Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo‐controlled clinical trials
Diabetes, Obesity and Metabolism · 2025
DOI: 10.1111/dom.16398 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Diabetes, Obesity and Metabolism, 2025. Verfasst von Yu Mi Kang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes and Hypertension and TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusett…. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Incretins, Hypoglycemic Agents. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, National Institute of Diabetes and Digestive and Kidney Diseases.
Abstract (Originalsprache)
Aims
This study compares the therapeutic efficacy, gastrointestinal (GI) adverse event (AE) rates and the relationship between the therapeutic efficacy and GI AEs in randomized, placebo‐controlled clinical trials (RCTs) of GLP‐1 RAs and the dual GLP‐1/GIP agonist tirzepatide. Materials and Methods A systematic PubMed search identified 38 phase 3 or 4 placebo‐controlled RCTs of exenatide (b.i.d. and q.w.), lixisenatide, liraglutide, dulaglutide, albiglutide, semaglutide (s.c. and oral) and tirzepatide with a total of 16 660 individuals with type 2 diabetes (T2D) across 104 study arms. Changes in HbA1c, fasting plasma glucose and body weight and the proportion of GI AEs (nausea, vomiting or diarrhoea) were calculated by agent, preparation and dose. The correlation between odds ratios (ORs) for GI AEs and the magnitude of therapeutic efficacy was assessed in a linear regression analysis.
Results
Baseline characteristics were similar across studies: mean age 57 ± 10 years, diabetes duration 8 ± 6 years, body mass index (BMI) 31.9 ± 5.8 kg/m 2 and HbA1c 8.2% ± 0.9%. HbA1c reductions ranged from −0.63% ± 0.03% (lixisenatide, 20 μg q.d.) to −1.79% ± 0.09% (tirzepatide, 15 mg q.w.; p < 0.0001). Weight reductions ranged from −0.75 ± 0.10 kg to −9.65 ± 0.56 kg. Despite the high variability in therapeutic efficacy, ORs for GI AEs were similar across compounds/preparations.
Conclusions
The magnitude of efficacy for intended therapeutic actions (HbA1c and body weight reduction) varied widely between incretin mimetic glucose‐lowering agents. However, larger therapeutic efficacy was not systematically associated with higher GI AE or drug discontinuation rates, indicating better tolerability of the more effective agents/preparations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Endocrinology, Diabetes and Hypertension and TIMI Study Group, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
- Diabetes, Endocrinology, Metabolism Section Medical Department I, Josef-Hospital, Ruhr University Bochum, Bochum, Germany.
- Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, South Korea.
- Institute for Clinical Chemistry and Laboratory Medicine, University Medicine Greifswald, Greifswald, Germany.
ORCID-Profile: Yu Mi Kang, Soo Lim, Michael A Nauck
Förderung
- NIDDK NIH HHS
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Kang, Y. M., Punov, V., Lim, S., & Nauck, M. A. (2025). Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo‐controlled clinical trials. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.16398
Vancouver
Kang YM, Punov V, Lim S, Nauck MA. Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo‐controlled clinical trials. Diabetes, Obesity and Metabolism. 2025. doi:10.1111/dom.16398
BibTeX
@article{Kang2025,
author = {Kang, Yu Mi and Punov, Viktoria and Lim, Soo and Nauck, Michael A},
title = {Comparative efficacy and tolerability of currently approved incretin mimetics: A systematic analysis of placebo‐controlled clinical trials},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
doi = {10.1111/dom.16398}
}
EUVIMED